Immucell (ICCC) Cash from Financing Activities (2010 - 2025)
Immucell's (ICCC) quarterly Cash from Financing Activities came in at -$394602.0 in Q4 2025, down 365.07% YoY from $148866.0 in Q4 2024, and down 16.85% on a QoQ basis from -$337689.0 in Q3 2025.
Immucell (ICCC) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Immucell (ICCC) has 16 years of Cash from Financing Activities data on file, last reported at -$394602.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 365.07% year-over-year to -$394602.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.2 million (down 142.06% YoY) and the FY2025 annual result came in at -$1.2 million, down 142.06% from the prior year.
- Cash from Financing Activities eased to -$394602.0 in Q4 2025, from -$337689.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $4.0 million in Q2 2021 to a low of -$403647.0 in Q1 2025.
- A 5-year average of $420742.0 and a median of -$185665.0 in 2021 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities slumped 528.91% — and 2022, when it jumped 1114.39%.
- Tracing ICCC's Cash from Financing Activities over 5 years: stood at -$194905.0 in 2021, then retreated by 27.35% to -$248209.0 in 2022, then declined by 29.5% to -$321433.0 in 2023, then surged by 146.31% to $148866.0 in 2024, then plunged by 365.07% to -$394602.0 in 2025.
- The last three Cash from Financing Activities figures came in at -$394602.0 (Q4 2025), -$337689.0 (Q3 2025), and -$76448.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -394,602.00 |
| Dec 31, 2025 | -394,602.00 |
| Sep 30, 2025 | -337,689.00 |
| Sep 30, 2025 | -337,689.00 |
| Jun 30, 2025 | -76,448.00 |
| Jun 30, 2025 | -76,448.00 |
| Mar 31, 2025 | -403,647.00 |
| Mar 31, 2025 | -403,647.00 |
| Dec 31, 2024 | 148,866.00 |
| Dec 31, 2024 | 148,866.00 |
| Sep 30, 2024 | 3.21 Mn |
| Sep 30, 2024 | 3.21 Mn |
| Jun 30, 2024 | -111,601.00 |
| Jun 30, 2024 | -111,601.00 |
| Mar 31, 2024 | -366,543.00 |
| Mar 31, 2024 | -366,543.00 |
| Dec 31, 2023 | -321,433.00 |
| Dec 31, 2023 | -321,433.00 |
| Sep 30, 2023 | 1.58 Mn |
| Sep 30, 2023 | 1.58 Mn |